EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2024

Jan Bell, Alicia Fajardo Lubian, Sally Partridge, Thomas Gottlieb, Jennifer Robson, Jonathan Iredell, Denise Daley, Geoffrey Coombs

Communicable Diseases Intelligence · 2025

DOI: 10.33321/cdi.2025.49.055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Jan Bell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Australian Group on Antimicrobial Resistance, Canberra, the Australian Capital Territory, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacterial Infections, Gram-Negative Bacteria, Bacteremia. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. From 1 January 2024 to 31 December 2024, fifty-five hospitals across Australia participated in the Australian Gram-negative Surveillance Outcome Program (GnSOP). A total of 10,340 isolates, comprising Enterobacterales (9,376; 90.9%), Pseudomonas aeruginosa (804; 7.7%) and Acinetobacter species (160; 1.4%), were tested using commercial automated methods. The results were analysed using European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2025). Key resistances reported are to the third-generation cephalosporin ceftriaxone in 14.9% of Escherichia coli and 10.5% of Klebsiella pneumoniae complex isolates. Resistance rates to ciprofloxacin were 15.4% for E. coli; 9.7% for the K. pneumoniae complex; 3.8% for the Enterobacter cloacae complex; and 8.8% for P. aeruginosa. Resistance rates to piperacillin–tazobactam were 7.5%, 10.3%, 25.2%, and 13.6% for the same four species/complexes, respectively. Thirty-nine Enterobacterales isolates from 38 patients were shown to harbour a carbapenemase gene: 21 with a blaNDM gene (blaNDM-5 [8]; blaNDM-1 [7]; blaNDM-7 [6]); eight with blaIMP-4; four with a blaOXA-181-like gene (blaOXA-181 [2]; blaOXA-484 [1]; blaOXA-1205 [1]); three with a blaOXA-48-like gene (blaOXA-48 [2]; blaOXA-244); two with blaKPC-2; and one with blaNDM-5 + blaOXA-484. Carbapenemase genes were also detected in two P. aeruginosa isolates (blaNDM-1 [1]; blaGES-5 [1]).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsGram-Negative Bacterial InfectionsGram-Negative BacteriaBacteremiaDrug Resistance, BacterialHumansAustraliaMicrobial Sensitivity TestsEpidemiological Monitoring

Stichwörter der Autor:innen

Australian Group on Antimicrobial ResistanceEnterobacterEscherichia coliKlebsiellaantimicrobial resistancebacteraemiagram-negative

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Australian Group on Antimicrobial Resistance, Canberra, the Australian Capital Territory, Australia.
  • Westmead Institute for Medical Research, Westmead, New South Wales, Australia; The University of Sydney, New South Wales, Australia.
  • Westmead Institute for Medical Research, Westmead, New South Wales, Australia; The University of Sydney, New South Wales, Australia; Westmead Hospital, Westmead, New South Wales, Australia.
  • The University of Sydney, New South Wales, Australia; Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia. thomas.gottlieb@health.nsw.gov.au.
  • Department of Microbiology, Sullivan Nicolaides Pathology, Bowen Hills, Queensland.
  • Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.

Zitieren

APA

Bell, J., Fajardo Lubian, A., Partridge, S., Gottlieb, T., Robson, J., Iredell, J., Daley, D., & Coombs, G. (2025). Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2024. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.055

Vancouver

Bell J, Fajardo Lubian A, Partridge S, Gottlieb T, Robson J, Iredell J, et al. Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2024. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.055

BibTeX
@article{Bell2025,
  author = {Bell, Jan and Fajardo Lubian, Alicia and Partridge, Sally and Gottlieb, Thomas and Robson, Jennifer and Iredell, Jonathan and Daley, Denise and Coombs, Geoffrey},
  title = {Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Surveillance Outcome Program (GnSOP) Bloodstream Infection Annual Report 2024},
  journal = {Communicable Diseases Intelligence},
  year = {2025},
  doi = {10.33321/cdi.2025.49.055}
}
Kostenlos starten →